^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + Campath (alemtuzumab) (CD52 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IBRUTINIB ENHANCES MACROPHAGE-DEPENDENT THERAPY RESPONSES OF ANTIBODY COMBINATION THERAPY VIA JAK2 INHIBITION OF TARGET B-CELLS
Published date:
06/12/2020
Excerpt:
To address Antibody-Dependent Cellular Phagocytosis (ADCP) J774A.1 macrophages in co-culture with MYC/Bcl2 Double-hit-lymphoma (hMB) cells or primary chronic lymphocytic leukemia (CLL) patient cell....we used the hMB humanized mouse model of Double-Hit B cell lymphoma and could observe prolonged survival of combination treatment of alemtuzumab and ibrutinib as compared to alemtuzumab monotherapy.
